Vimian Group Revenue and Competitors

Location

N/A

Total Funding

Veterinary

Industry

Employee Data

  • Vimian Group has 28 Employees.(i)
  • Vimian Group grew their employee count by 8% last year.

Vimian Group's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$15M2056%N/AN/A
#2
N/A288%N/AN/A
Add Company

What Is Vimian Group?

Vimian is a global and fast-growing group of innovation-driven companies that share a passion for making a positive impact through improving animal health. Together, we put science, technology and our customers’ needs at the centre of everything we do to deliver effective solutions to animals and veterinary professionals around the world. We bring together pioneering and entrepreneurial businesses in animal health, with an aim to create a uniquely diversified proposition of products and services of the highest standard. Our group covers four essential areas within animal health: Specialty Pharma (www.nextmune.com), Diagnostics (www.indical.com), Veterinary Services (www.vetfamily.com) and MedTech (www.movora.com). Vimian provides individual businesses with access to our networks, expertise, infrastructure and capital to accelerate innovation and growth. We are as passionate about supporting leadership within our existing businesses, as we are about welcoming new partners to the Vimian family – together helping us make an even greater impact improving animal health. Headquartered in Stockholm, Sweden, Vimian and our family of companies serve over 15,000 customers in +70 countries and employ more than 400 people.

keywords:N/A

N/A

Total Funding

28

Number of Employees

N/A

Revenue (est)

8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Vimian Group News

2022-04-17 - Veterinary Healthcare Market to Expand at a CAGR of 8.10% Over 2022-2027

Looking forward, IMARC Group expects the market to reach a value of US$ 59.37 Billion by 2027, ... INDICAL Bioscience GmbH (Vimian Group)

2022-04-06 - Is Vimian Group AB (publ)'s (STO:VIMIAN) 2.2% ROE Worse Than Average?

One way to conceptualize this is that for each SEK1 of shareholders' capital it has, the company made SEK0.02 in profit. Does Vimian Group Have...

2022-03-22 - Vimian Group Acquires Veterinary Allergy Business in the UK

Vimian Group's Specialty Pharma segment Nextmune has acquired the veterinary allergy division, Avacta Animal Health, from AvactaGroup plc.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A2833%N/A
#2
N/A280%N/A
#3
$3.5M28-3%N/A
#4
N/A2856%N/A
#5
$4.4M28-26%N/A